What Is Ipamorelin? Ghrelin Receptor Mechanism & Research Applications

TL;DR: Ipamorelin (sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), commonly called the ghrelin receptor. Its defining pharmacological property is high selectivity for GH secretion with minimal co-stimulation of cortisol or prolactin — making it the preferred GHRP tool compound for studies focused on GH axis effects without confounding HPA axis activation.

What Is Ipamorelin?

Ipamorelin is a fifth-generation growth hormone releasing peptide (GHRP). It was developed to improve on earlier GHRPs (GHRP-6, GHRP-2, hexarelin) by achieving equivalent GH-releasing potency with significantly less co-secretion of cortisol, prolactin, and ACTH — side effects that complicate experimental interpretation in neuroendocrine research.

The pentapeptide sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 incorporates non-natural amino acids (Aib, D-2-naphthylalanine, D-phenylalanine) that confer protease resistance and GHSR-1a selectivity. The molecular weight of ipamorelin is 711.87 Da, and its CAS number is 170851-70-4. It is supplied as a lyophilized white powder and is typically reconstituted in sterile or bacteriostatic water.

Unlike CJC-1295, which acts at the GHRH receptor on pituitary somatotrophs, ipamorelin acts at a distinct receptor — GHSR-1a — that is expressed on both pituitary somatotrophs and in extrapituitary tissues including the hypothalamus, stomach, and hippocampus. The two receptor systems converge at the somatotroph level to produce synergistic GH release.

Mechanism of Action

Ipamorelin activates GHSR-1a, a Gαq/11-coupled class A GPCR (distinct from the Gαs-coupled class B receptors of the GHRH and GLP-1 families). GHSR-1a coupling to Gαq drives phospholipase C (PLC) activation, IP3 generation, and intracellular calcium mobilization from the endoplasmic reticulum.

Pituitary GH Release via Calcium Signaling

In pituitary somatotrophs, GHSR-1a activation by ipamorelin triggers IP3-mediated Ca2+ release from the ER and voltage-gated L-type Ca2+ channel opening. The resulting cytoplasmic Ca2+ spike drives GH exocytosis from dense-core secretory granules. This calcium-dependent mechanism is distinct from the cAMP/PKA pathway used by CJC-1295 via GHRHR, and the two pathways potentiate each other synergistically in co-administration experiments.

Somatostatin Inhibition at the Hypothalamus

GHSR-1a is also expressed on hypothalamic neurons. Ipamorelin administration reduces somatostatin (SRIF) release from the hypothalamus, removing the tonic brake on pituitary GH secretion. This dual action — direct pituitary stimulation plus hypothalamic somatostatin suppression — contributes to ipamorelin’s robust GH-releasing efficacy despite its small pentapeptide size.

Selectivity: Why Ipamorelin Spares Cortisol and Prolactin

Earlier GHRPs (GHRP-6, hexarelin) activated both GHSR-1a and co-stimulated corticotroph ACTH/cortisol release and lactotroph prolactin release through incompletely characterized mechanisms. Ipamorelin’s unique pentapeptide scaffold does not produce this off-target activation, as demonstrated in dose-response studies in rodent and primate models. This selectivity makes it the preferred GHRP in studies where confounding HPA axis activation must be minimized.

Ipamorelin Research Applications

Ipamorelin’s clean selectivity profile makes it the GHRP of choice in growth hormone research where HPA axis contamination would confound metabolic, anabolic, or neuroendocrine endpoints.

• GHSR-1a pharmacology: Receptor binding assays, cAMP and Ca2+ mobilization assays, and β-arrestin recruitment studies at GHSR-1a to characterize ghrelin receptor pharmacology and identify functional biased agonists.
• CJC-1295 combination studies: Co-administration of ipamorelin (GHSR-1a) with CJC-1295 (GHRHR) in rodent studies to characterize synergistic GH secretion from dual receptor co-stimulation — a widely used paradigm in growth hormone axis research.
• GH pulsatility studies: Short half-life (~2 hours) makes ipamorelin appropriate for acute GH pulse studies where tonic stimulation (as with CJC-1295) is not desired.
• Ghrelin axis research: Used alongside acylated ghrelin and des-acyl ghrelin as part of the ghrelin receptor pharmacology toolkit, distinguishing GHSR-1a-specific signaling from non-receptor ghrelin effects on energy metabolism.
• Bone and lean mass studies: In vivo models using ipamorelin to drive GH/IGF-1 axis activation while avoiding cortisol-driven catabolism, allowing cleaner measurement of anabolic endpoints in bone mineral density and lean body mass experiments.

For procurement details, see the bulk Ipamorelin product page.

Ipamorelin vs. Other GHRPs

The GHRP family includes GHRP-2, GHRP-6, hexarelin, and ipamorelin. All are GHSR-1a agonists but differ meaningfully in selectivity:

• GHRP-6: Robust GH release with significant ghrelin-like appetite stimulation and moderate cortisol co-secretion. Useful for appetite circuit research where ghrelin mimicry is desired.
• GHRP-2: Higher GH potency than GHRP-6, but also higher ACTH/cortisol co-secretion — a confound in metabolic studies that require clean GH axis readouts.
• Hexarelin: The most potent GHRP, but significant cortisol, ACTH, and prolactin co-secretion limits its utility in clean GH axis studies.
• Ipamorelin: Comparable GH efficacy to GHRP-2 with markedly less cortisol and prolactin co-secretion — the preferred choice when HPA axis contamination is a concern.

Researchers selecting a GHRP should match compound to experimental question. If appetite circuit research is the goal, GHRP-6’s appetite stimulation is a feature, not a bug. If clean GH/IGF-1 axis characterization is needed without HPA axis interference, ipamorelin is the appropriate choice.

Key Takeaways

1. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates GHSR-1a (the ghrelin receptor) on pituitary somatotrophs and hypothalamic neurons.
2. Mechanism: Gαq/PLC/IP3/Ca2+ pathway driving GH exocytosis — distinct from CJC-1295’s Gαs/cAMP/PKA GHRHR mechanism; the two pathways synergize when co-administered.
3. Defining pharmacological property: high GH selectivity with minimal cortisol, ACTH, or prolactin co-secretion — the key advantage over GHRP-2, GHRP-6, and hexarelin.
4. Short half-life (~2 hours) supports pulsatile GH stimulation protocols; co-use with CJC-1295 adds a sustained GHRHR component for maximal synergistic GH output.
5. Non-natural amino acids (Aib, D-2-Nal, D-Phe) in the sequence confer proteolytic resistance and GHSR-1a selectivity over related receptors.

Buy Bulk Ipamorelin → · CJC-1295 Research Guide · BPC-157 Research Guide · All Research Guides · Full Bulk Peptides Catalog

Published by Bulk Peptides, a US-based wholesale supplier of research-grade peptides. All products are for in vitro laboratory research use only (RUO) — not for human or veterinary use. Last reviewed August 2026.